Project description:Data regarding the clinical outcomes of immune checkpoint inhibitor (ICI) therapy and profiles of the tumor immune microenvironment (TIME) in non-clear-cell renal cell carcinoma (nccRCC) remain limited. Here, we retrospectively compared the effectiveness profiles of first-line ICI combination therapy between patients with clear-cell RCC (ccRCC) and those with nccRCC.
Project description:Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. Advanced kidney cancer has a high chance of recurrence and metastasis after surgery. This project performed proteomic analysis on advanced ccRCC tumor samples to describe the molecular landscape of advanced tumors.